achieve cost-effectiveness at conventional willingness-to-pay thresholds (3, 4) , prompting interest in this novel pricing model.
Objective: To examine the effect of outcomes-based pricing on the cost-effectiveness of PCSK9 inhibitors among eligible patients with ASCVD.
Methods and Findings: We used the Cardiovascular Disease Policy Model to estimate the cost-effectiveness of PCSK9 inhibitors among 8.9 million U.S. adults aged 40 to 84 years with ASCVD and low-density lipoprotein cholesterol levels of at least 1.81 mmol/L (70 mg/dL) despite statin therapy (3, 4) . This model is an established state-transition Markov model that uses epidemiologic, clinical trial, registry, and claims data to project the clinical and economic burden of cardiovascular disease among U.S. adults (details are available in the Supplement and Supplement Tables 1 to 6 [available at http://tiny .ucsf.edu/CVDpolicymodel]).
We compared baseline statin therapy with the addition of ezetimibe (a lipid-lowering agent with a similar indication) or a PCSK9 inhibitor from a health system perspective and a lifetime analytic horizon. The primary outcome was the incremen- tal cost-effectiveness ratio (ICER), calculated as incremental health care costs (in 2017 U.S. dollars) per quality-adjusted life-year (QALY) gained, with a willingness-to-pay threshold of $100 000 per QALY. We modeled 3 scenarios that refund progressively larger amounts to the payer for a drug failure. For each MI, stroke, or cardiovascular death that took place within 5 years of initiating a PCSK9 inhibitor, we examined scenarios in which the manufacturer would refund 1 year of drug costs, all drug costs incurred before the event, or drug costs plus inpatient costs for MI or stroke. The effectiveness of PCSK9 inhibitors was modeled on the findings of the FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial, which randomly assigned 27 564 participants with ASCVD receiving statin therapy to additional treatment with evolocumab or placebo (5). Evolocumab reduced a composite end point of MI, stroke, and cardiovascular death (hazard ratio, 0.85 [95% CI, 0.79 to 0.92]) over 2.2 years. Our base case included brand-name drug costs after deductions for rebates and discounts ( Table 1) . Sensitivity analyses incorporated drug costs based on the Federal Supply Schedule and the cost of generic ezetimibe. Future costs and QALYs were discounted at 3% per year.
Without the refund, the ICER for a PCSK9 inhibitor added to a statin was $324 000 per QALY compared with ezetimibe added to a statin. Each of the 3 pricing schemes improved the ICER only marginally, but all ICERs remained substantially higher than $100 000 per QALY ( Table 2) . The scenario in which the manufacturer would refund drug costs plus inpatient costs for MI or stroke yielded the largest refund; however, the ICER for a PCSK9 inhibitor added to a statin improved by only 3.1% ($314 000 per QALY). Assuming drug prices that were based on the Federal Supply Schedule or generic pricing for ezetimibe did not meaningfully alter these results (Supplement Tables 7 and 8 [available at http://tiny .ucsf.edu/CVDpolicymodel]).
Discussion: Outcomes-based pricing has been proposed as a novel approach to reducing drug costs, improving uptake, and increasing manufacturer accountability for uncertain treatment responses (1). However, our analysis suggests that it does not meaningfully reduce costs or improve the costeffectiveness of PCSK9 inhibitors. Three factors make such pricing less relevant for preventive medications.
First, event rates in prevention are generally low and preventive treatment is lifelong. The annual ASCVD event rate in those with a history of this condition is approximately 3%; among 100 eligible patients, 97 would thus incur the full costs each year and refunds would apply to only 3 patients.
Second, attributing an event to the failure of a preventive medication is complicated. In practice, events eligible for reimbursement would depend on clinical context (for example, whether stroke in the setting of poorly controlled blood pressure would be considered a failure of a PCSK9 inhibitor).
Finally, patients in nongovernmental insurance markets frequently change plans. Tracking events eligible for reimbursements and payers to whom the reimbursement is due over the long term would therefore be challenging.
Broad use of PCSK9 inhibitors among the 8.9 million U.S. adults with ASCVD who met trial criteria would substantially increase drug expenditures nationally (3). Outcomes-based pricing would not reduce this effect. Although we did not examine other eligible populations, the similarity in event rates and the cost-effectiveness of PCSK9 inhibitors in patients intolerant of statins or with heterozygous familial hypercholesterolemia suggests that results would probably be similar (3). We did not model the programmatic costs of tracking events and processing refunds and therefore may have overestimated savings.
Although outcomes-based pricing may have a role in other settings, our analysis of its application to PCSK9 inhibitorseffective preventive medications with a high price tag-shows the potential limitations of this approach for expensive preventive therapies.
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